公开(公告)号：US20130210855A1

公开(公告)日：2013-08-15

申请号：US13568003

申请日：2012-08-06

申请人： Michael T. NORDSIEK ,  Sharon F. LEVY ,  James H. LEE ,  James H. KULP ,  Kodumudi S. BALAJI ,  Tze-Chiang MENG ,  Jason J. WU ,  Valyn S. BAHM ,  Robert BABILON

发明人： Michael T. NORDSIEK ,  Sharon F. LEVY ,  James H. LEE ,  James H. KULP ,  Kodumudi S. BALAJI ,  Tze-Chiang MENG ,  Jason J. WU ,  Valyn S. BAHM ,  Robert BABILON

IPC分类号： A61K31/4745

CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/7061 ,  A61K31/437 ,  A61K31/47 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

摘要翻译： 用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c] 喹诺酮-4-胺，即咪喹莫特，用于治疗短暂持续时间的光化性角化病，比现在由美国食品和药物管理局（FDA）批准的市售的5％咪喹莫特乳膏所述， 被公开和描述。 更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案 还公开和描述了用于Aldara 5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。

公开(公告)号：US20120289538A1

公开(公告)日：2012-11-15

申请号：US13559473

申请日：2012-07-26

申请人： Michael T. NORDSIEK ,  Sharon F. LEVY ,  James H. LEE ,  James H. KULP ,  Kodumudi S. BALAJI ,  Tze-Chiang MENG ,  Jason J. WU ,  Valyn S. BAHM ,  Robert BABILON

发明人： Michael T. NORDSIEK ,  Sharon F. LEVY ,  James H. LEE ,  James H. KULP ,  Kodumudi S. BALAJI ,  Tze-Chiang MENG ,  Jason J. WU ,  Valyn S. BAHM ,  Robert BABILON

IPC分类号： A61K31/4745 ,  A61P17/12 ,  A61P15/00

CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

摘要翻译： 用于局部或透皮递送1异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-4 - 胺，即咪喹莫特，以美国食品和药物管理局（FDA）批准的治疗时间短于目前为商业可用的5％咪喹莫特乳膏治疗的生殖器/肛门周围疣进行治疗， 描述。 更具体地说，低剂量强度的咪喹莫特制剂，以递送有效剂量的咪喹莫特，用于治疗生殖器/肛周疣，具有可接受的安全性和对于患者使用而言比目前由美国食品和药物当前批准的给药方案更短和更方便的给药方案 还公开和描述了用于治疗生殖器/肛周疣的Aldara 5％咪喹莫特乳膏的给药（FDA）。

公开(公告)号：US08236816B2

公开(公告)日：2012-08-07

申请号：US13181499

申请日：2011-07-12

申请人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

发明人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC分类号： A01N43/42 ,  A01N43/52

CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/7061 ,  A61K31/437 ,  A61K31/47 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

摘要翻译： 用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c] 喹诺酮-4-胺，即咪喹莫特，以治疗短暂持续时间治疗的光化性角化病，比现在由美国食品和药物管理局（FDA）批准的市售ALDARA 5％咪喹莫特乳膏所规定的 公开和描述。 更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案 还公开和描述了用于ALDARA 5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。

公开(公告)号：US20110319811A1

公开(公告)日：2011-12-29

申请号：US13168796

申请日：2011-06-24

申请人： Michael T. Nordsiek ,  Sharon F. Levy ,  James Hurn-Joung Lee ,  James H. Kulp ,  Tze-Chiang Meng ,  Jason J. Wu ,  Robert Babilon ,  Kodumudi S. Balaji ,  Valyn S. Bahm

发明人： Michael T. Nordsiek ,  Sharon F. Levy ,  James Hurn-Joung Lee ,  James H. Kulp ,  Tze-Chiang Meng ,  Jason J. Wu ,  Robert Babilon ,  Kodumudi S. Balaji ,  Valyn S. Bahm

IPC分类号： A61M37/00

CPC分类号： A61B18/02 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/1075 ,  A61K31/437 ,  A61K33/00 ,  A61K47/10 ,  A61K47/26 ,  A61K2300/00

摘要： The present invention is directed to the use of complementary or combination lesion-directed therapy, such as cryosurgery, and field-directed therapy, such as low dose imiquimod topical therapy with short durations, in combination to treat actinic keratosis (“AK”). In carrying out the present invention, the lesion-directed and field-directed therapies may be applied sequentially or concomitantly, in accordance with the present invention. The novel complementary or combination AK therapy contemplated by the present invention: (1) significantly improves clearance of cryosurgery-treated Aks; (2) treats subclinical AK lesions; (3) treats those visible AK lesions in excess of that cryosurgery can actually treat in a single treatment due to, e.g., patient tolerance, provider treatment limits and/or cryosurgery cost to the patient; and (4) enhances sustained clearance overall, as compared to mono AK lesion-directed therapy.

摘要翻译： 本发明涉及使用互补或组合的病变导向疗法，例如冷冻手术和局部定向治疗，例如具有短持续时间的低剂量咪喹莫特局部治疗，以组合治疗光化性角化病（“AK”）。 在实施本发明时，根据本发明可以依次或伴随地应用病变导向和场导向疗法。 本发明考虑的新型互补或组合AK治疗：（1）显着改善冷冻治疗的Aks的清除率; （2）治疗亚临床AK病变; （3）由于例如患者耐受性，提供者治疗限度和/或对患者的冷冻手术费用，治疗超过该冷冻手术的那些可见的AK病变可以在单次治疗中实际治疗; 和（4）与单AK病变导向治疗相比，总体上增强了持续清除率。

公开(公告)号：US20110263635A1

公开(公告)日：2011-10-27

申请号：US13182433

申请日：2011-07-13

申请人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

发明人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC分类号： A61K31/437 ,  A61P17/12

CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/7061 ,  A61K31/437 ,  A61K31/47 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

摘要翻译： 用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c] 喹诺酮-4-胺，即咪喹莫特，用于治疗短暂持续时间的光化性角化病，比现在由美国食品和药物管理局（FDA）批准的市售的5％咪喹莫特乳膏所述， 被公开和描述。 更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案 还公开和描述了用于Aldara 5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。

公开(公告)号：US20180128580A1

公开(公告)日：2018-05-10

申请号：US15347155

申请日：2016-11-09

申请人： HENRY E. PASLEY ,  JASON J. WU ,  LI-JUN SHEN

发明人： HENRY E. PASLEY ,  JASON J. WU ,  LI-JUN SHEN

IPC分类号： F41H13/00 ,  A41D1/00 ,  A41D19/00 ,  H05K5/00 ,  H02H5/08

CPC分类号： F41H13/0018 ,  A41D1/005 ,  A41D19/01505 ,  F41H1/02 ,  F41H13/0087

摘要： Disclosed is the glove worn by a user for incapacitating an individual. The glove includes a housing configured to cover palm and fingers of the user, the housing having a palm side layer for covering the front part of the hand and a backside layer for covering the back part of the hand; a circuit control unit configured on the backside layer having an anesthesia electrical wave generator for generating anesthesia electrical wave for incapacitating the individual; a power source configured on the palm side layer to power the circuit control unit; wherein the palm side layer having a first cutting resistance layer to protect the user's hand from foreign particles; a flexible electrode layer configured on at least one portion of the first cutting resistance layer to transfer the generated anesthesia electrical wave received from the anesthesia electrical wave generator to the individual; a pressure sensor configured beneath the cutting resistance layer to activate the flexible electrode layer only on exceeding pre-stored pressure value while grasping the individual by the user; and a first knitting cloth layer configured to be the innermost layer next to the palm of the user; wherein the backside layer having a backside leather layer configured to protect user's hand; and a second knitting cloth layer configured to be the innermost layer next to the back of the hand of the user.

公开(公告)号：US20120329825A1

公开(公告)日：2012-12-27

申请号：US13559456

申请日：2012-07-26

申请人： Michael T. NORDSIEK ,  Sharon F. LEVY ,  James H. LEE ,  James H. KULP ,  Kodumudi S. BALAJI ,  Tze-Chiang MENG ,  Jason J. WU ,  Valyn S. BAHM ,  Robert BABILON

发明人： Michael T. NORDSIEK ,  Sharon F. LEVY ,  James H. LEE ,  James H. KULP ,  Kodumudi S. BALAJI ,  Tze-Chiang MENG ,  Jason J. WU ,  Valyn S. BAHM ,  Robert BABILON

IPC分类号： A61K31/437 ,  A61P17/12

CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

摘要翻译： 用于局部或透皮递送1异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-4-酮的制剂和方法， 胺，即咪喹莫特，以目前规定的治疗生殖器/肛门周围疣的时间短于现有的美国食品和药物管理局（FDA）批准的5％咪喹莫特乳膏市售的方法，公开和描述 。 更具体地说，低剂量强度的咪喹莫特制剂，以递送有效剂量的咪喹莫特，用于治疗生殖器/肛周疣，具有可接受的安全性和对于患者使用而言比目前由美国食品和药物当前批准的给药方案更短和更方便的给药方案 还公开和描述了用于治疗生殖器/肛周疣的Aldara 5％咪喹莫特乳膏的给药（FDA）。

公开(公告)号：US08242155B2

公开(公告)日：2012-08-14

申请号：US13182433

申请日：2011-07-13

申请人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

发明人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC分类号： A01N43/52 ,  A01N43/42

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

公开(公告)号：US08222270B2

公开(公告)日：2012-07-17

申请号：US13179315

申请日：2011-07-08

申请人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

发明人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC分类号： A01N43/42 ,  A01N43/52

CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/7061 ,  A61K31/437 ,  A61K31/47 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available ALDARA 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for ALDARA 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

摘要翻译： 用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c] 喹诺酮-4-胺，即咪喹莫特，以治疗短暂持续时间治疗的光化性角化病，比现在由美国食品和药物管理局（FDA）批准的市售ALDARA 5％咪喹莫特乳膏所规定的 公开和描述。 更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案 还公开和描述了用于ALDARA 5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。

公开(公告)号：US20110263636A1

公开(公告)日：2011-10-27

申请号：US13184556

申请日：2011-07-17

申请人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

发明人： Michael T. Nordsiek ,  Sharon F. Levy ,  James H. Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC分类号： A61K31/4745 ,  A61P17/00 ,  A61P35/00

CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/7061 ,  A61K31/437 ,  A61K31/47 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14

摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

摘要翻译： 用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c] 喹诺酮-4-胺，即咪喹莫特，用于治疗短暂持续时间的光化性角化病，比现在由美国食品和药物管理局（FDA）批准的市售的5％咪喹莫特乳膏所述， 被公开和描述。 更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案 还公开和描述了Aldara的5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。